Neurology Diagnostic Criteria
NMO SPECTRUM-UK, with the support of our Pharmaceutical partners, will endeavour to keep you fully up to date with all relevant medical advances and clinical trials, as we work together in pursuit of our mutual aims: easing the existing condition and, hopefully, finding the cure. For more information on current clinical trials please bookmark this page for later reference.
New Research into the treatment of NMO/NMOSD
Do you have NMO or NMOSD?
Have you experienced a relapse in the last 12 months?
If the answer to both of these questions is Yes, you may be able to take part in a new clinical research study.
The SAkura Sky study is looking at the safety and efficacy of an investigational medication for Neuromyelitis Optica and Neuromyeltis Optica Spectrum Disorder (NMO/NMOSD) that is given as an injection under the skin once a month along with
your current therapy .
You may be eligible to take part in SAkura Sky the study if you:
- Are between 12 and 17 years of age, and
- Have been diagnosed with NMO or NMOSD, and
- Are currently being treated with one of the following agents:
- Azathioprine, or
- Mycophenolate mofetil, or
- Oral corticosteroids, or
- Azathioprine + Oral corticosteroids, or
- Mycophenolate mofetil + Oral corticosteroids
- Do not have any evidence of MS or other demyelinating disease, and
- Do not have an active infection (excluding fungal infections of nail beds or dental infection) within the last 4 weeks.
At each visit, the study team will monitor your symptoms and health. If you decide to participate in the study you will either receive the new investigational agent or a placebo injection. The visit frequency to the study center is once a month. You will be reimbursed for your travel expenses.
If you are interested in learning more about the SAkura Sky study, please contact:
Tony Hughes-McCann on 07807831349 or via email at email@example.com
For more information on the trial, please visit: